Journal of Rheumatic Diseases

Table. 3.

Change in WPAI at weeks 12 and 24 after initiation of adalimumab

Instrument Mean±SD Change from baseline p-value*

Mean±SD 95% CI
Percent overall work impairment (%)
Baseline 58.27±26.19
Week 12 37.03±26.27 −19±32 −32, −5 0.0098
Week 24 32.31±25.86 −25±31 −40, −11 0.0015
Percent activity impairment (%)
Baseline 61.71±24.98
Week 12 45.47±27.52 −15±31 −22, −8 <0.0001
Week 24 38.59±28.35 −25±34 −33, −16 <0.0001

WPAI: Work Productivity and Activity Impairment, SD: standard deviation, CI: confidence interval. *p-value is from the paired t-test testing the mean change.

J Rheum Dis 2021;28:68~75 https://doi.org/10.4078/jrd.2021.28.2.68
© J Rheum Dis